Fig. 3From: Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trialDistribution of SARS-CoV-2 neutralizing antibody. A Per-protocol analysis, B intention-to-treat analysis. The table shows the percentages of SARS-CoV-2 neutralizing antibody in each groupBack to article page